BioCentury
ARTICLE | Company News

Mesoblast, Teva deal

June 20, 2016 7:00 AM UTC

Teva returned rights to Mesoblast’s mesenchymal precursor cell (MPC) technology for cardiovascular indications, including lead program MPC-150-IM. According to Mesoblast, Teva’s decision was based on “strategic reasons aligned to their core therapeutic areas of focus.” Mesoblast said Teva still retains a stake in Mesoblast and retains rights to the MPC technology for CNS indications, which Mesoblast said is in Teva’s core areas of focus. MPC-150-IM, which comprises allogeneic adult MPCs, is in Phase III testing to treat congestive heart failure (CHF). ...